SCHEDULE: Point72 Affiliates Disclose 8.7% Stake in Korro Bio

Steven A. Cohen's Point72 entities have filed an amended Schedule 13G, disclosing an aggregate beneficial ownership of 8.7% in Korro Bio, Inc. as of June 30, 2025.

Summary

• Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., Point72 Biotech Private Investments, LLC, Differentiated Ventures Investments, LLC, 72 Investment Holdings, LLC, and Steven A. Cohen have filed an Amendment No. 2 to their Schedule 13G.
• The filing reports beneficial ownership of Common Stock, par value $0.001 per share, in Korro Bio, Inc. (CUSIP: 500946108).
• As of June 30, 2025, Steven A. Cohen, through the various Point72 entities, beneficially owns an aggregate of 816,905 shares of Korro Bio, Inc. Common Stock.
• This aggregate ownership represents 8.7% of the class of securities.
• Point72 Asset Management, L.P. and Point72 Capital Advisors, Inc. each report shared voting and dispositive power over 540,074 shares, representing 5.8% of the class.
• Point72 Biotech Private Investments, LLC, Differentiated Ventures Investments, LLC, and 72 Investment Holdings, LLC each report shared voting and dispositive power over 276,831 shares, representing 2.9% of the class.
• The filing states that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of beneficial ownership by a major institutional investor, indicating continued significant investment in Korro Bio. It does not contain new positive or negative operational or financial information, but the sustained stake by a prominent investor can be viewed as a neutral to slightly positive signal.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of beneficial ownership by a significant institutional investor in a publicly traded biotechnology company. It reflects an ongoing investment position rather than a new strategic move within the broader biotech industry.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.

Key Dates

Keywords

Korro Bio, Point72, Steven A. Cohen, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Biotech